PR View by Josh Shabtai

Share this article:
Chances are you've used Wikipedia, maybe to research a topic of interest—or to see what people are saying about your brand. Hopefully, you've never used it in an attempt to game the system, as Microsoft infamously did a few months ago.

Wikipedia's impact is enormous. Google any major brand and you'll pull up a Wikipedia entry within the first results, meaning that a community of thousands has a significant degree of control over the perception of your brand.

The Wikipedia community is a tightly knit bunch that is deeply distrustful of marketers. Because of past abuses, they're extremely vigilant against PR folks' edits.

So where does that leave us? Here's a guide to working with Wikipedia. First, search your clients' Wikipedia pages. Simple enough. Repeat regularly. Because entries are edited by a potentially huge community, they may change daily or hourly. Monitor for changes by adding an RSS feed on your entry. Note inaccurate or damaging information.

This is important: No matter what, RESIST THE URGE TO EDIT IT. If you've ever seen Ghostbusters, think of this as the equivalent of “crossing the streams.”

Dig a little deeper. Click on the “history” tab at the top of an entry page and track all of the changes that have been made to your entry. You can even see who made such edits. Visit their personal profiles and note who's been sticking up for you, fighting you, posting neutral information. Consider what you've just learned about them. Why are they posting about your client? Do they appear receptive to conversing with institutions?

Keep an eye on this critical source of information about your brand and think strategically about how to work WITH this influential community instead of pushing information DOWN ONTO them.

Josh Shabtai is senior new media specialist at Ketchum

Share this article:
You must be a registered member of MMM to post a comment.

MM&M EBOOK: PATIENT ACCESS

Patient access to pharmaceuticals is a tale of two worlds—affordability has improved for the majority, while the minority is hampered by cost, distribution and red tape. To provide marketers with a well-rounded perspective, MM&M presents this e-book chock full of key insights. Click here to access it.

More in Channel

Five things for pharma marketers to know: Monday, September 15

Five things for pharma marketers to know: ...

Pharma has sought 76 meetings with FDA over biosimilars; Gilead licenses Sovaldi to India generic drugmakers; Pfizer and Ranbaxy Lipitor lawsuit dismissed.

Liraglutide, aiming for new indication, gets new name

Liraglutide, aiming for new indication, gets new name

Why Novo Nordisk is choosing not to leverage Victoza's brand equity as it seeks a weight-loss indication for liraglutide.

Five things for pharma marketers to know: Friday, September 12

Five things for pharma marketers to know: Friday, ...

An FDA panel voted in favor of liraglutide for weight loss; Allergan investors backing an attempted takeover of the firm crossed a critical threshold; and 100 million health wearables are ...